Allogeneic umbilical cord blood red cell concentrates: An innovative blood product for transfusion therapy of preterm infants

Autor: Bianchi, Maria, Giannantonio, Carmen, Spartano, Serena, Fioretti, Maria, Landini, Alessandra, Molisso, A, Tesfagabir, Gm, Tornesello, Assunta, Barbagallo, O, Valentini, Cg, Vento, Giovanni, Zini Tanzi, Gina, Romagnoli, Costantino, Papacci, Patrizia, Teofili, L., Teofili, Luciana
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Male
Erythrocyte transfusion
medicine.medical_specialty
Adult red blood cells
Availability of umbilical cord blood
Preterm infants
Safety of umbilical cord blood
Umbilical cord blood transfusion
Birth Weight
Feasibility Studies
Female
Fetal Blood
Follow-Up Studies
Gestational Age
Humans
Infant
Newborn
Intensive Care Units
Neonatal
Prospective Studies
Erythrocyte Transfusion
Infant
Premature
Pediatrics
Perinatology and Child Health
Developmental Biology
Umbilical cord
Pediatrics
Blood product
Neonatal
Medicine
Prospective cohort study
Premature
Red Cell
business.industry
Obstetrics
TransfusionTherapy
Follow up studies
Gestational age
Infant
Perinatology and Child Health
Newborn
Intensive Care Units
Settore MED/15 - MALATTIE DEL SANGUE
medicine.anatomical_structure
Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA
Transfusion therapy
business
Popis: Background: Preterm infants often receive blood transfusions early in life. In this setting, umbilical cord blood (UCB) might be safer than adult blood (A) with respect to infectious and immunologic threats. Objectives: To evaluate, as a first objective, the feasibility of fulfilling transfusion needs of preterm infants with allogeneic UCB red blood cell (RBC) concentrates and, as a secondary objective, to assess the safety of allogeneic cord blood transfusions. Methods: At the Neonatal Intensive Care Unit and the UNICATT Cord Blood Bank of ‘A. Gemelli' Hospital in Rome, a prospective study was carried out over a 1-year period, enrolling newborns with gestational age ≤30 weeks and/or birth weight ≤1,500 g requiring RBC transfusions within the first 28 days of life. At first transfusion, patients were assigned to receive UCB-RBCs or A-RBCs depending on the availability of ABO-Rh(D)-matched UCB-RBC units. The same regimen (UCB-RBC or A-RBC units) was thereafter maintained, unless ABO-Rh(D)-matched UCB-RBC units were not available. Results: Overall, 23 UCB-RBC units were transfused to 9 patients; the requests for UCB-RBC units were met in 45% of patients at the first transfusion and in 78% at the subsequent transfusions. At a median follow-up of 57 days (range 6-219), no acute or delayed transfusion-related adverse events occurred. Hematocrit gain after transfusion and time intervals between transfusions were similar in the UCB-RBC and A-RBC group, as well. Conclusions: Transfusing allogeneic UCB-RBC units in preterm infants appears a feasible and safe approach, although the transfusion needs of our study population were not completely covered. More data are necessary to validate this novel transfusion practice. © 2014 S. Karger AG, Basel
Databáze: OpenAIRE
Externí odkaz: